kidney transplantation recipients with preexisted anti-HLA antibody
Conditions
Interventions
Rituximab administration single dose administration of 200mg/body before renal transplantation Plasma exchange three to four times replaced by albumin Immunoglobulin administration IVIG 2-3g/kg w
3000)
Sponsors
Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Kidney transplantation recipients with HLA-donor specific antibody at Division of Nephrology and hypertension, department of internal medicine, and Urology, The Jikei University of Medicine. 2)The patient who can have a decision about the participation of this study voluntary, and understand consent brief and other explanation documents.
Exclusion criteria
Exclusion criteria: 1) The patients with serious hypersensitivity or medical history of anaphylaxis for the products derived from mouse protein, Rituximab, immunoglobulin, and an integrent of the albumin to prepare plasma exchange. 2) The patients whom the medical attendant judged when the exacerbation of the sign exceeded benefit of Rituximab among them who have severe infectious diseases, a cardiac dysfunction, respiratory diseases, or a bone marrow dysfunction. 3) The patients with an medical history of the drug hypersensitivity and the allergic to albumin (preparation for plasma exchange), Rituximab or immunoglobulin whom the medical attendant judged when these adverse effects exceeded the benefits of these medications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| graft failure rate | — |
Secondary
| Measure | Time frame |
|---|---|
| patient survival rate rate of allograft rejection adverse effect rate | — |
Countries
Japan
Contacts
Public ContactYasuyuki Nakada
The Jikei University of Medicine Division of Nephrology and Hypertension, Department of Internal Medicine
Outcome results
None listed